ClinicalTrials.gg
CompletedNCT02655549Updated Jul 11, 2017

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

A Phase 1 interventional study of Px563L, RPA563, or placebo in Anthrax, sponsored by Pfenex, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Pfenex, Inc · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Anthrax with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Anthrax · United States.

Enrollment
27th of 40
54 · median 97
Started
2015
the only one that year
Phase 1
23 of 47
none open now
Registered
30th of 47
by date

Among the 47 studies in Anthrax with a site in United States, this one is the 27th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2015, is one of 23 in phase 1, and was the 30th registered.

Anthrax

75 studies on the registry are indexed under Anthrax; 12 are open to participants now.

Browse Anthrax studies →

Open to participants now

1 of the 47 studies in Anthrax with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Anthrax studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Anthrax with a site in United States, or all of them as a file.
02

Study summary

The trial investigates Px563L and RPA563, two formulations of a novel anthrax vaccine.

Read the detailed description

This is a Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of Px563L or RPA563 administered intramuscularly. All subjects will be followed for safety and tolerability for 393 days after the initial vaccination. Immunogenicity analyses will be performed for up to 182 days, including an interim analysis based on Day 70 results, after the initial vaccination.

03

Conditions studied

  • Anthrax

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to read and understand the consent process and sign an form (ICF).
  • Females or males between the ages of 18 and 55, inclusive, at the time of informed consent.
  • Healthy or with stable medical conditions not requiring continuous medication.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant or breastfeeding.
  • A history of anthrax disease or receipt of an anthrax vaccine at any time in the past, exposure to or infection with B. anthracis, or has received any anthrax vaccine or treatment (e.g., monoclonal antibodies, anthrax immune globulin).
  • Positive test for (HIV), or (surface antigen).
  • History of any malignant neoplasm or receipt of anti-neoplastic agents within the last 5 years, with the exception of adequately treated, localized or in situ non-melanoma of the skin (e.g., basal cell carcinoma) or of the cervix.
  • History of immunodeficiency, chronic illness requiring continuous or frequent medical intervention, disease, bleeding disorder, hemoglobinopathy, prior solid organ or bone marrow transplant, or any known history in the past 5 years of cardiac disease.
  • Evidence of alcohol abuse (i.e., requiring treatment) or substance abuse (i.e., any use of illicit drugs) within 6 months prior to screening.
  • History of severe allergy (e.g., anaphylaxis) to latex or rubber.
  • Subjects who have significant scarring, tattoos, abrasions, rash, or other skin abnormality at the planned vaccination site that could interfere with evaluation of injection site..
  • Use of any systemic or other agents within 2 years prior to screening; or use of topical, intranasal, or inhaled corticosteroids for ≥10 consecutive days within 1 year prior to screening.
  • Administration of any licensed vaccines within 30 days prior to screening.
  • History of anaphylaxis or other serious adverse reaction to vaccines.
  • Donation or loss of >500 mL of blood or donation of plasma within 2 months of screening, or recipient of blood or blood products within 2 months of screening.
  • Present or former member of US military or reservist who may have or will receive the licensed anthrax vaccine, or who has served in any military arena from January 1990 through present time.
  • May be at risk for exposure to anthrax or may be required to receive the licensed anthrax vaccine (e.g., postal workers).
  • Has previously participated in any anthrax vaccine or anti-protective antigen (PA) monoclonal antibody clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Cohort 1 of Px563L, RPA563, or placebo

    Intramuscular injections of Px563L, RPA563, or placebo

    Biological: Px563L, RPA563, or placebo

  • Experimental
    Cohort 2 of Px563L, RPA563, or placebo

    Intramuscular injections of Px563L, RPA563, or placebo

    Biological: Px563L, RPA563, or placebo

  • Experimental
    Cohort 3 of Px563L, RPA563, or placebo

    Intramuscular injections of Px563L, RPA563, or placebo

    Biological: Px563L, RPA563, or placebo

Interventions

  • BiologicalPx563L, RPA563, or placebo

    Two intramuscular injections

06

What researchers measure

Primary outcomes

  1. Adverse events (AE) and adverse events of special interest (AESI) for vaccines

    Time frame: 393 days

Secondary outcomes

  1. Anthrax toxin neutralizing antibody (TNA) 50% neutralization factor (NF50) value

    Time frame: 182 days

07

Study locations

1 site
  • Quintiles Phase One Services
    Overland Park, Kansas 66211, United States
08

References and documents

Publications

  • Schneider JC, Chen HC, Bautista E, Retallack D. Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults. Vaccine. 2021 Oct 8;39(42):6333-6339. doi: 10.1016/j.vaccine.2021.08.075. Epub 2021 Sep 17. PubMed 34544599 ↗

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jun 2017, 18 months.

Of 11 phase 1 interventional studies under Anthrax, half reached primary completion within 14 months of starting (the median); a quarter within 8 and three quarters within 18. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2016
First posted
Jan 14, 2016
StartActual
Dec 2015
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02655549
Lead sponsor
Pfenex, Inc
Collaborators
Department of Health and Human Services
Responsible party
Sponsor
First posted
Jan 14, 2016
Start date
Dec 2015
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Jul 11, 2017

Study contacts

Barbara K Lomeli, M.D.
principal investigator · Quintiles Phase One Services, LLC
Hubert C Chen, M.D.
study director · Pfenex, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion